» Articles » PMID: 18078456

Intracellular Signaling Pathways Involved in Cell Growth Inhibition of Human Umbilical Vein Endothelial Cells by Melatonin

Overview
Journal J Pineal Res
Publisher Wiley
Specialty Endocrinology
Date 2007 Dec 15
PMID 18078456
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Melatonin, an indolamine mainly produced in the pineal gland, has received a great deal of attention in the last decade because of its oncostatic effects, which are due to its immunomodulatory, antiproliferative, antioxidant and its possible antiangiogenesis properties. Herein, we document its antiproliferative action on human umbilical vein endothelial cells (HUVECs). Moreover, the possible cell signaling pathways when melatonin inhibited HUVEC proliferation were explored in this study. Primary HUVECs were isolated, cultured, purified and identified before the studies were performed. HUVECs were found to possess G-protein-coupled membrane receptors for melatonin (MT1 and MT2) and also nuclear melatonin receptors (RORalpha and RORbeta, especially RORbeta). No obvious expression of RORgamma was found. We investigated the membrane receptors and several intracellular signaling pathways including mitogen-activated protein kinases (MAPK)/extracellular signal-related kinases (ERK), phosphoinositol-3-kinase (PI3K)/Akt and protein kinases C (PKC) involved in antiproliferative action of melatonin on HUVECs. The blockade of these pathways using special inhibitors decreased cell growth. Furthermore, the constitutive activation of nuclear factor kappa B (NF-kappaB) contributed to the proliferation of HUVECs. High concentrations of melatonin inhibited both NF-kappaB expression and its binding ability to DNA, possibly through inactivation of ERK/Akt /PKC pathways. Taken together, high concentrations of melatonin markedly reduced HUVEC proliferation; the antiproliferative action of melatonin was closely correlated with following pathway: melatonin receptors/ERK/PI3K/Akt/PKC/ NF-kappaB.

Citing Articles

Melatonin protects TEGDMA-induced preodontoblast mitochondrial apoptosis via the JNK/MAPK signaling pathway.

Yu Q, Hua R, Zhao B, Qiu D, Zhang C, Huang S Acta Biochim Biophys Sin (Shanghai). 2024; 56(3):393-404.

PMID: 38308473 PMC: 10984853. DOI: 10.3724/abbs.2023263.


Melatonin attenuates high glucose‑induced endothelial cell pyroptosis by activating the Nrf2 pathway to inhibit NLRP3 inflammasome activation.

Wang X, Wang W, Zhang R, Ma B, Ni L, Feng H Mol Med Rep. 2023; 27(3).

PMID: 36799176 PMC: 9942260. DOI: 10.3892/mmr.2023.12958.


Melatonin as adjunctive therapy in patients admitted to the Covid-19.

Karimpour-Razkenari E, Naderi-Behdani F, Salahshoor A, Heydari F, Alipour A, Baradari A Ann Med Surg (Lond). 2022; 76:103492.

PMID: 35287296 PMC: 8908573. DOI: 10.1016/j.amsu.2022.103492.


Melatonin mitigates the adverse effect of hypoxia during myocardial differentiation in mouse embryonic stem cells.

Lee J, Yoo Y, Lee B, Jeong S, Tran D, Jeung E J Vet Sci. 2021; 22(4):e54.

PMID: 34313039 PMC: 8318788. DOI: 10.4142/jvs.2021.22.e54.


Cyst Reduction by Melatonin in a Novel Model of Polycystic Kidney Disease.

Millet-Boureima C, Rozencwaig R, Polyak F, Gamberi C Molecules. 2020; 25(22).

PMID: 33238462 PMC: 7700119. DOI: 10.3390/molecules25225477.